Integral Investment Advisors Inc. Boosts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Integral Investment Advisors Inc. grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 38.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,581 shares of the medical research company's stock after acquiring an additional 997 shares during the quarter. Integral Investment Advisors Inc.'s holdings in Thermo Fisher Scientific were worth $1,782,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in TMO. Handelsbanken Fonder AB grew its holdings in Thermo Fisher Scientific by 5.2% in the first quarter. Handelsbanken Fonder AB now owns 393,531 shares of the medical research company's stock worth $195,821,000 after purchasing an additional 19,311 shares during the last quarter. Petredis Investment Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 1.0% in the 1st quarter. Petredis Investment Advisors LLC now owns 7,199 shares of the medical research company's stock worth $3,582,000 after purchasing an additional 72 shares in the last quarter. Ameliora Wealth Management Ltd. increased its position in Thermo Fisher Scientific by 6.5% during the 1st quarter. Ameliora Wealth Management Ltd. now owns 558 shares of the medical research company's stock valued at $278,000 after buying an additional 34 shares in the last quarter. Simplicity Wealth LLC raised its stake in Thermo Fisher Scientific by 26.7% in the first quarter. Simplicity Wealth LLC now owns 1,452 shares of the medical research company's stock valued at $723,000 after buying an additional 306 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Thermo Fisher Scientific by 22.0% in the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after acquiring an additional 877 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on TMO shares. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Stifel Nicolaus lowered their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Barclays lowered their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Finally, Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $605.30.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO traded up $6.00 on Tuesday, reaching $414.53. The stock had a trading volume of 2,573,612 shares, compared to its average volume of 1,914,596. The business's 50-day moving average price is $419.12 and its two-hundred day moving average price is $494.94. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12-month low of $390.50 and a 12-month high of $627.88. The company has a market cap of $156.48 billion, a P/E ratio of 25.08, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Thermo Fisher Scientific's quarterly revenue was up .2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.11 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.